Management strategies and prognosis of patients ineligible for transcatheter mitral valve replacement.

Background: Transcatheter mitral valve replacement (TMVR) faces anatomical challenges, currently limiting widespread adoption.

Objectives: To describe the natural history and prognosis of patients ineligible for various TMVR devices.

Methods: During a 4-year period (2019-2023) 3 TMVR devices (SAPIEN M3, Intrepid and Alta Valve) became available at a single institution (The Christ Hospital, Cincinnati, OH) in the setting of pivotal clinical trials or early feasibility study.